These studies aim to leverage the differences between tumor and normal tissues to achieve preferential tumor targeting and mediate CD137 crosslinking, thereby achieving potent activation while reducing systemic toxicity and maintaining antitumor efficacy [24]. This evidence concerns the gene TNFRSF9 and neoplasm.